Form 8-K - Current report:
SEC Accession No. 0001628280-24-046867
Filing Date
2024-11-12
Accepted
2024-11-12 08:03:59
Documents
15
Period of Report
2024-11-12
Items
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ovid-20241112.htm   iXBRL 8-K 30488
2 EX-99.1 ovid2024q3exhibit991.htm EX-99.1 62956
6 ovid-therapeutics_logo750s.jpg GRAPHIC 23227
  Complete submission text file 0001628280-24-046867.txt   263032

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ovid-20241112.xsd EX-101.SCH 1779
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ovid-20241112_lab.xml EX-101.LAB 22548
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ovid-20241112_pre.xml EX-101.PRE 13044
17 EXTRACTED XBRL INSTANCE DOCUMENT ovid-20241112_htm.xml XML 2914
Mailing Address 441 NINTH AVENUE, 14TH FLOOR NEW YORK NY 10001
Business Address 441 NINTH AVENUE, 14TH FLOOR NEW YORK NY 10001 212-776-4381
Ovid Therapeutics Inc. (Filer) CIK: 0001636651 (see all company filings)

EIN.: 465270895 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38085 | Film No.: 241443530
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)